Nevro raises $120M follow-on to fund painful diabetic neuropathy commercial launch

Summary

Nevro completed a $120M follow-on equity offering to fund the commercial launch of HF10 therapy for painful diabetic neuropathy following FDA approval. The offering was oversubscribed with participation from existing institutional investors. Proceeds will fund dedicated PDN sales team expansion, patient education programs, and managed care coverage negotiations.